Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

(2021) Flora Pirozzi et al.   Current Oncology Reports

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis

(2020) Abdulaali R. Almutairi et al.   Frontiers in Oncology

Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma

(2020) Arnold Lee et al.   DRUGS

Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls

(2020) Eli P. Darnell et al.   Current Oncology Reports

Autoimmune complications of immunotherapy: pathophysiology and management

(2020) Karmela K Chan et al.   BMJ-British Medical Journal

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

(2020) Danny Rischin et al.   Journal for ImmunoTherapy of Cancer

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

(2020) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

(2019) Iosune Baraibar et al.   DRUG SAFETY

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

(2019) Alessio Cortellini et al.   Clinical Lung Cancer

Cardiovascular toxicities associated with immune checkpoint inhibitors

(2019) Jiun-Ruey Hu et al.   CARDIOVASCULAR RESEARCH

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

(2019) Blake M. Warner et al.   ONCOLOGIST

Kidney Complications of Immune Checkpoint Inhibitors: A Review

(2019) Roman Shingarev et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review

(2019) Jeroen M.k. de Filette et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Which place for avelumab in the management of urothelial carcinoma?

(2019) Mathieu Larroquette et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review

(2019) Richeek Pradhan et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control

(2019) Michael S. Hughes et al.   Cancer Medicine

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology

(2019) Dong-Yi Chen et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?

(2019) Mark A. Perazella et al.   KIDNEY INTERNATIONAL

Immuno-oncology drug development goes global

(2019) Jia Xin Yu et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy

(2019) Marie Kostine et al.   RHEUMATOLOGY

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy

(2019) Noha Abdel-Wahab et al.   RHEUMATOLOGY

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

(2018) Yinghao Zhao et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

(2018) James Larkin et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

(2018) Michael R. Migden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade

(2018) Kerry Reynolds et al.   ONCOLOGIST

CHECKPOINT INHIBITOR IMMUNE THERAPY

(2018) Lauren A. Dalvin et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

(2018) Sandra P. D’Angelo et al.   JAMA Oncology

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Immune checkpoint inhibitors and cardiovascular toxicity

(2018) Alexander R Lyon et al.   LANCET ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thyroid disorders induced by checkpoint inhibitors

(2018) Silvia Martina Ferrari et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Product review: avelumab, an anti-PD-L1 antibody

(2018) Julie M. Collins et al.   Human Vaccines & Immunotherapeutics

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis

(2018) Ke Ma et al.   Frontiers in Pharmacology

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

(2017) Sandra P. D’Angelo et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma

(2017) Iris Fried et al.   JOURNAL OF NEURO-ONCOLOGY

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

(2017) Arjun V Balar et al.   LANCET ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

(2017) David J. Byun et al.   Nature Reviews Endocrinology

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

(2017) Laura C. Cappelli et al.   ARTHRITIS CARE & RESEARCH

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis

(2017) Sarah Chuzi et al.   Cancer Management and Research

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

(2016) Anushree C. Shirali et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

(2016) Laura C Cappelli et al.   ANNALS OF THE RHEUMATIC DISEASES

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

(2016) Vincent Sibaud et al.   CURRENT OPINION IN ONCOLOGY

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

(2016) L. Marthey et al.   Journal of Crohns & Colitis

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

(2016) Frank B. Cortazar et al.   KIDNEY INTERNATIONAL

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy

(2016) Lisa Kottschade et al.   MELANOMA RESEARCH

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab

(2016) Jeremy W. Vandiver et al.   Targeted Oncology

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

(2016) Masahide Okamoto et al.   Journal of Diabetes Investigation

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

(2016) Noha Abdel-Wahab et al.   PLoS One

Systematic review: colitis associated with anti-CTLA-4 therapy

(2015) A. Gupta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

(2015) J. Larkin et al.   EUROPEAN JOURNAL OF CANCER

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

(2015) Rosalba Camicia et al.   Molecular Cancer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

(2014) B. Liao et al.   NEURO-ONCOLOGY

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

(2013) Salvatore Maria Corsello et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy

(2013) D. B. Johnson et al.   Cancer Immunology Research

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

(2011) Zhen Zeng et al.   PLoS One

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

(2010) Yan Zhang et al.   Cellular & Molecular Immunology

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

(2010) A. A. Sarnaik et al.   CLINICAL CANCER RESEARCH

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization

(2010) Q. Zhou et al.   JOURNAL OF IMMUNOLOGY

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells

(2009) James D. Lord et al.   DIGESTIVE DISEASES AND SCIENCES

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

(2009) Troy Dillard et al.   Pituitary

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology